Having acquired French company RPG Aventis early this year, Ranbaxy is now eyeing small branded urology molecules in the United States.
"We are looking at acquiring small branded molecules...urology molecules in the US," Brian Tempest, chief executive officer and managing director of Ranbaxy Laboratories told PTI.
The company is also looking at expanding and building the generic business, he said.
Tempest said Ranbaxy already had a group which was actively looking at inlicensing and another looking at acquisitions so that the company can grow both organically and inorganically.
The pharmaceutical company, which is targeting to become a $5 billion firm in terms of revenue by 2012, has a healthy product pipeline with about five molecules in Phase I and investigational new drug application stage.
"We are going to look at filing some IND this year and some next year," Tempest said without divulging specific details about the molecules.
The company is also looking at small biotech companies for taking lead molecules which can then be further worked upon, Ranbaxy's new R&D head Rajendra Kumar said.